Description
Indication & Scope
Vunakizumab Injection treats adult patients with moderate to severe plaque psoriasis suitable for systemic treatment.
- Mechanism: Monoclonal antibody neutralizes pro-inflammatory IL-17 cytokines, inhibits excessive keratinocyte proliferation and skin inflammatory response.
- Drug class: Anti-IL-17 monoclonal antibody, dermatologic biologic anti-inflammatory drug.
- Clinical use: Induction and maintenance treatment of moderate-severe plaque psoriasis.
| Generic Name | Vunakizumab Injection |
| Brand Name | AnDaJing |
| Ingredient | Vunakizumab Injection |
| Dosage Form | Injection |
| Package | 120mg(1ml)*1 syringe/box; 240mg(2ml)*1 syringe/box |
| Conditions Treated | Moderate to severe plaque psoriasis |
| Taboos | 1. Clinically significant active bacterial, fungal or viral severe infections
2. History of severe hypersensitivity reactions to any component of the product 3. Active untreated tuberculosis 4. Patients with severe primary immunodeficiency |
| Place of origin | China |
| Prescription type | Prescription-only |
| Storage Conditions | Store at 2°C ~ 8°C refrigerated, forbidden freezing and high temperature exposure |
| Manufacturer | ShengDiYa Biopharmaceutical, Ltd |
| Registration Authority | National Medical Products Administration (NMPA), China |
| Approval number | S20240049 |
| Approval Date | OCT 22, 2024 |
| Shelf Life | 24 months |
How to use ?
Recommended Dose: Initial loading doses, then regular maintenance subcutaneous injections.
Time: Fixed cycle dosing for long-term disease management.
Instructions for use: Subcutaneous injection into abdomen, thigh or upper arm.
Interaction: Live vaccines are not recommended during treatment; monitor infection risk when combined with immunosuppressants.
Side effects: Injection site reactions, upper respiratory tract infections, headache, fatigue, mild superficial fungal infection.
Important Notice
This product should be administered only by qualified healthcare professionals in accordance with the approved prescribing information and local clinical guidelines. Dosage and administration may vary depending on patient condition, indicatiaon, and regional regulatory requirements.
Packaging & Shipping
Packaging
Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.
Shipping Methods
Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.
Export Support
Certificate of Analysis
GMP Certificate
Commercial Invoice
Packing List & CPP
Cold Chain Logistics
Customs Documentation
Scientific and regulatory sources
FAQ
What is the main clinical use of Vunakizumab Injection?
It is used for induction and maintenance therapy in adult patients with moderate to severe plaque psoriasis suitable for systemic treatment.
How does Vunakizumab Injection relieve psoriatic symptoms?
It neutralizes pro-inflammatory IL-17 cytokines, inhibits excessive keratinocyte proliferation and suppresses skin inflammatory responses.
What type of vaccine is forbidden during treatment with Vunakizumab Injection?
Live vaccines are not recommended for patients receiving Vunakizumab due to increased infection risk.
Who cannot take Vunakizumab Injection treatment?
Patients with active severe infections, untreated tuberculosis, severe immunodeficiency or drug hypersensitivity are contraindicated.
AnDaJing® | Vunakizumab Injection | Plaque Psoriasis | DengYueRX
INN: Vunakizumab Injection
Indications: Treatment of moderate to severe plaque psoriasis
Dosage Form: Injection
Strength: 120mg(1ml)/syringe; 240mg(2ml)/syringe
